Johnson & Johnson Announces Quarterly Dividend of $1.34 (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Wednesday, July 15th. Stockholders of record on Tuesday, August 25th will be paid a dividend of 1.34 per share on Tuesday, September 8th. This represents a c) annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, August 25th.

Johnson & Johnson has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 64 years. Johnson & Johnson has a dividend payout ratio of 48.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Johnson & Johnson to earn $12.63 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 42.4%.

Johnson & Johnson Price Performance

JNJ stock opened at $247.55 on Thursday. The business’s 50-day moving average is $238.64 and its two-hundred day moving average is $234.20. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $159.80 and a 1 year high of $269.43. The firm has a market capitalization of $595.90 billion, a P/E ratio of 28.62, a P/E/G ratio of 2.42 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.02 billion. During the same quarter last year, the company earned $2.77 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds have recently made changes to their positions in JNJ. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. United Bank boosted its holdings in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC grew its position in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares during the last quarter. Wealth Group Ltd. increased its holdings in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after acquiring an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. raised its position in Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.